Researchers find better way to predict childhood brain tumor outcomes

January 24, 2002

(Boston, MA) - A distinctive "signature" of genes turned on and off greatly improves predictions of who has the best chance of survival of the most common type of childhood malignant brain tumor, according to a new study by researchers at Childrens Hospital Boston and their colleagues. If verified by other studies over the next several years, the gene expression profile may help children survive the malignant brain tumor with fewer serious side effects. The study also shows that medulloblastoma has key molecular differences from other brain tumors, which eventually may help researchers find more targeted treatment. The study is published in the Jan. 24 issue of the weekly journal Nature.

"Over the past 20 years, survival from medulloblastomas has dramatically improved," says pediatric neurologist Scott Pomeroy, first author of the paper. "In modern clinical trials, more than 80 percent of 'good-risk' patients survive. Nearly 100 percent of the survivors, however, have learning disabilities, most have hearing loss and cataracts, and the majority are unable to live independent of their families as adults. A major goal of current treatment trials, then, is to reduce the level of radiation to lessen toxicity without compromising survival in good-risk patients."

Now, risk is defined by clinical criteria, such as the presence of metastases on MRI scanning, excessive tumor remaining in the brain after surgery, and examination of tumor tissue under a microscope. "Our predictor is much more accurate than these clinical criteria," says Pomeroy, also an associate professor at Harvard Medical School.

About 2,000 children a year are diagnosed with medulloblastoma, with diagnosis verified at the time of surgery. For this study, researchers examined gene expression patterns from 99 patient tumor samples of three different types of brain tumors. In addition to distinguishing tumor types from each other, the study found strong expression of a signaling protein known as Sonic Hedgehog, which is supposed to be turned off after it performs its crucial functions during fetal brain developing. Pomeroy's study confirms other work in fruit flies and humans implicating mutations in the Hedgehog signaling pathway as responsible for turning normal cerebellum into cancerous cells.

"The new work is an exciting example of how useful genomic studies can be to classify different tumor types, to arrive at a prognosis using gene activities in tumor cells, and to identify relationships between normal cells and tumor cells," says Matthew Scott, a developmental biologist at Stanford University School of Medicine and the Howard Hughes Medical Institute whose research group linked the Hedgehog signaling pathway to medulloblastoma.

The study is part of a cluster of recent papers from a group of Boston researchers from several research centers applying new genomic tools to cancer. It turns out that simultaneous measurement of thousands of genes expressed in a tumor sample may help explain why some people respond to cancer treatments and others don't. Also known as "transcriptional profiling," the new techniques may provide a more reliable diagnosis. It may uncover previously unrecognized kinds of cancer and provide new discovery tools to explore and ultimately to interfere with the basic machinery of cancer. Some of the studies are so preliminary that biological meaning is still largely conjecture; others serve up good possibilities for imminent clinical testing.

This study is particularly interesting because researchers couldn't find the signature patterns by simpler cluster analysis methods. So, Pomeroy and his colleagues developed a pattern recognition algorithm that "trained" a powerful computer to learn the difference between patients who survived and those who didn't.

"The bottom line is that there exists a gene expression signature of outcome in childhood medulloblastoma, and this signature is detectable at the time of diagnosis, before patients receive treatment," says pediatric oncologist Todd Golub, senior author of this paper. "It is important not only for medulloblastoma, but because it suggests that such signatures are likely to be detectable for other cancers as well." Golub is an assistant professor of Pediatrics at Harvard Medical School and holds joint appointments at Children's Hospital Boston, Dana-Farber Cancer Institute and the Whitehead Institute.

"The clinical implementation of genomics-based outcome predictors must await confirmation in independent data sets, and the models may need to be modified as treatment regimens evolve," says Pomeroy. "Nevertheless, this work illustrates how genomic technologies have the potential to advance treatment planning beyond the empiric, toward a more molecularly defined, individualized approach to medicine."
Children's Hospital Boston is the nation's premier pediatric medical center. Founded in 1869 as a 20-bed hospital for children, today it is a 300-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. In addition, more than 100 outpatient specialty clinics are located at Children's. Children's Hospital is the primary pediatric teaching affiliate of Harvard Medical School, home to the world's leading pediatric research enterprise, and the largest provider of health care to the children of Massachusetts. For more information about the hospital visit:

For Further Information: Bess Andrews, Children's Hospital, 617-355-6420 (
Donna Burtanger, Harvard Medical School, 617-432-3991 (

Harvard Medical School

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to